NASDAQ: KMTSKestra Medical Technologies Ltd Stock
$16.67+0.17 (+1.03%)
Updated Jul 30, 2025
KMTS Price
$16.67
Fair Value Price
N/A
Market Cap
$855.98M
52 Week Low
$13.25
52 Week High
$26.15
P/E
-3.25x
P/B
4.17x
P/S
9.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$59.82M
Earnings
-$113.81M
Gross Margin
40.5%
Operating Margin
-177.12%
Profit Margin
-210.9%
Debt to Equity
0.44
Operating Cash Flow
-$78M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KMTS Overview
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KMTS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
KMTS
Ranked#41 of 45
Ranked#41 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.45 | B | |
| $82.96 | B | |
| $5.71 | B |
Be the first to know about important KMTS news, forecast changes, insider trades & much more!
KMTS News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KMTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KMTS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KMTS is poor value based on its book value relative to its share price (4.17x), compared to the US Medical Instruments & Supplies industry average (3.59x)
P/B vs Industry Valuation
KMTS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KMTS due diligence checks available for Premium users.
Valuation
KMTS fair value
Fair Value of KMTS stock based on Discounted Cash Flow (DCF)
Price
$16.67
Fair Value
-$22.50
Undervalued by
174.09%
KMTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KMTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.25x
Industry
36.98x
Market
32.18x
KMTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.17x
Industry
3.59x
KMTS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KMTS's financial health
Profit margin
Revenue
$17.2M
Net Income
-$51.1M
Profit Margin
-321.2%
KMTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KMTS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$295.7M
Liabilities
$90.3M
Debt to equity
0.44
KMTS's short-term assets ($255.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KMTS's short-term assets ($255.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KMTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.7M
Investing
-$7.8M
Financing
$214.7M
KMTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KMTS vs Medical Stocks
Kestra Medical Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.